Compare Agilysys Inc (AGYS) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Quest Diagnostics Inc — how do they compare? Agilysys Inc trades at $107.16 (market cap $3.00B), while Quest Diagnostics Inc trades at $238.51 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 8.7× Agilysys Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | DGX | |
|---|---|---|
Market Cap | $3.00B | $26.21B |
Sector | Technology | Health |
52-Week High | $141.12 | $238.50 |
52-Week Low | $62.19 | $173.49 |
Enterprise Value | $2.90B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $106.14, down 0.79% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $118.33. Recent Q1 2026 earnings beat expectations with EPS of $0.63 versus $0.4971, and the company raised its full-year outlook, driven by strong subscription revenue growth and deployment progress with key clients like Marriott.
The outlook is positive given robust earnings momentum and 100% buy ratings from analysts, though high valuation multiples (P/E of 70.01) and negative net cash flow in 2025 pose risks. Upside potential exists if subscription-led growth continues, but investors should monitor execution against elevated expectations.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
